ViaDerma, a publicly traded pharmaceutical company, is revolutionizing transdermal technology with its patented dual carrier transdermal delivery system.
In this interview, Dr. Christopher Otiko, the founder of ViaDerma, discusses the company’s lead product, Vitastem Ultra, which is one of the most powerful topical antibiotics in the world.
The transdermal technology allows medication to be transported at 10 times the strength and depth of other products, delivering rapid results to the desired site of action.
The founder also highlights how the technology can be applied to various industries, including healthcare professionals in hospitals, surgery centers, wound care, dermatology, pet care, assisted living, and cosmetics.
Additionally, our interview covers how ViaDerma can help reduce healthcare-acquired infections and heal various skin conditions, from diabetic wounds to acne and psoriasis.
So, let’s dive in!
ViaDerma & Vitastem Ultra
What made you decide to start up your company ViaDerma?
I really wanted produce medication that could eventually help save a lot of lives. So, I then decided to start ViaDerma to help heal diabetic wounds and eventually other infectious skin diseases too.
What makes your topical delivery system superior to others?
Our transdermal technology uses a patent-pending, specialized combination of ingredients which has hacked the delivery formula enabling medicine to be transported at 10x the strength and depth of other products in the marketplace today. Our unique formula stimulates the cell wall in such a way this it is up to 10x more permeable than normal. This allows for substantially more medicine to enter the cell, which then overwhelms and kills the bacteria so quickly that it does not have ample time to adapt and develop a resistance. This highly concentrated, rapid delivery of the medicine to the site of treatment is why patients see results within 24 hours using our lead product Vitastem Ultra, versus 5 to 7 days (or longer), when compared to competitor products.
What are 3 key differentiators of your product offerings?
Well, there’s quite a few more differentiators than three. But I would say these are some solid benefits of our lead product Vitastem Ultra (first aid & topical antibiotic) that uses our transdermal technology.
- Vitastem Ultra is the only antibiotic in the world that kills with both a physical and chemical mechanism, with a unique ability to kill drug resistant bacteria.
- Vitastem Ultra kills all known bacteria it has ever been tested against, including common antibiotic-resistant MRSA (flesh-eating bacteria) and Staph Infection.
- Vitastem Ultra has a unique ability to heal and regenerate tissue unlike any other medication on the market. It’s all about the chemistry we use…
Aside from surgical & diabetic wounds, what skin conditions can you treat?
Our lead product Vitastem was originally designed over 10 years ago to heal diabetic ulcers and wounds. However, our solutions have proven to be incredibly successful at treating acne, eczema, psoriasis, burns, boils, cuts & scrapes, to finger & toenail fungus, and more serious antibiotic-resistant bacterial infections like staph & MRSA (flesh-eating bacteria).
How can ViaDerma help reduce HAIs (healthcare acquired infections)?
HAIs effect millions of people every year. It’s a really big issue and something we can help drastically reduce. Especially with our lead product Vitastem Ultra which is highly effective at killing harmful bacteria like staph & MRSA, which can cause very serious health complications and even death. There are not really any other products on the market at the level of killing staph infection or MRSA as effectively as Vitastem Ultra can. We can help save hundreds of thousands of lives due to common HAIs like staph & MRSA alone in the US each year.
How many industries is your topical delivery system a solution for?
There are several industries we can provide solutions to. Mainly to healthcare professionals in hospitals, surgery centers, wound care, dermatology, pet care, assisted living (nursing homes), and cosmetics. Our tech can be licensed to create new products, while we’re also exploring expanding our Vitastem Ultra sales efforts to physician offices, hospitals, wound care centers, and nursing homes too. In addition to these, ViaDerma recently announced that we will be launching a new minoxidil hair regrowth product later this year after the exceptional test results we’ve generated at regrowing hair.
Moving Forward
ViaDerma is revolutionizing transdermal technology with its patent pending dual carrier transdermal delivery system, which allows medication to be transported at 10 times the strength and depth of other products in the market.
After conducting our interview with the founder of ViaDerma, we were left eager to discover more about their remarkable product. The discussion shed light on the exceptional advantages of their flagship solution, Vitastem Ultra, which possesses the capacity to eradicate drug-resistant bacteria, rejuvenate skin tissue, and effectively manage various skin ailments.
ViaDerma’s innovative transdermal technology also holds the promise of mitigating the incidence of healthcare-associated infections, a pressing concern that affects millions of individuals annually.
Furthermore, the company’s transdermal delivery technology can be applied to various industries, including healthcare, pet care, and cosmetics.
ViaDerma’s commitment to innovation and patient care is evident in their continued efforts to develop new products, such as their upcoming minoxidil hair regrowth product.
In conclusion, our encounter with the founder of ViaDerma has left us eagerly anticipating the company’s next move in the market. With their innovative transdermal delivery technology that holds tremendous potential to enhance the lives of many millions worldwide, ViaDerma is a promising pharmaceutical company. We are thrilled to witness their continued growth and look forward to their future endeavors.
